FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which ... is an important step in pain management.

It will be sold under the brand name Journavx (JOUR-nah-vix) to treat moderate to severe, acute, short-term pain in adults. It was approved Jan. 30, but is not available for prescription yet.

The oral NaV1.8 inhibitor has been cleared under the Journavx brand name with a broad label to treat adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management ... its own Nav inhibitor Journavx (suzetrigine) approved ...

Vertex's Journavx launch may boost awareness for ... local analgesic currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension ...

If that is a signal of reduced efficacy in chronic pain it could be a drag on Journavx peak sales potential ... Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises ...

The company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important milestones in its growth strategy. Journavx, a non-opioid ...